South Korea-based bio-healthcare company Dx&Vx (DXVX) announced on Thursday the acceleration of its development programme for a universal COVID-19 vaccine, following the recent acquisition of related technology.
The company says that the vaccine is designed to provide immunity against both current and future variants of the coronavirus, amid a new wave of COVID-19 cases worldwide.
DXVX secured the universal vaccine technology late last year. The vaccine under development uses a virus-like particle (VLP) platform, which is claimed to offer greater stability and ease of storage compared to mRNA vaccines.
Theoretically, it has the potential to prevent infections caused by all known and future COVID-19 variants.
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Zoetis announces EU approval for Portela to relieve osteoarthritis pain in cats
4basebio synthetic DNA used in Phase I/II mRNA therapy trial
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Sanofi reports data showing high-dose flu vaccine delivers superior protection for older adults
GC Biopharma granted CMO rights for Curevo Vaccine's shingles vaccine
TransCode acquires Polynoma and secures USD25m investment from CK Life Sciences
Wasatch BioLabs adds three Oxford Nanopore-developed research-use-only assays to service portfolio
GSK and IQVIA expand vaccine track with local data to drive targeted public health action